Title: Use of focal radiotherapy boost for prostate cancer and perceived barriers toward its implementation: a survey

Authors: Allison Y. Zhong[1], Asona J. Lui[1], Matthew S. Katz[2], Alejandro Berlin[3], Sophia C. Kamran[4], Amar U. Kishan[5], Vedang Murthy[6], Himanshu Nagar[7], Daniel Seible[8], Bradley J. Stish[9], Alison C. Tree[10], Tyler M. Seibert[1,11,12]

[1]Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA, USA
[2]Department of Radiation Medicine, Lowell General Hospital, Lowell, MA, USA
[3]Radiation Medicine Program, Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada
[4]Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
[5]Department of Radiation Oncology, UCLA, Los Angeles, CA, USA
[6]Tata Memorial Centre, Mumbai, India
[7]Weill Cornell Medicine, New York, NY, USA
[8]Anchorage & Valley Radiation Therapy Centers, Anchorage, AK, USA
[9]Department of Radiation Oncology, Mayo Clinic, Rochester, MN, USA
[10]The Institute of Cancer Research/The Royal Marsden NHS Foundation Trust, London, UK
[11]Department of Radiology, University of California San Diego, La Jolla, CA, USA
[12]Department of Bioengineering, University of California San Diego, La Jolla, CA, USA

Abstract:

Background: In a recent phase III randomized control trial (FLAME), delivering a focal radiotherapy (RT) boost to tumors visible on MRI was shown to improve outcomes for prostate cancer patients without increasing toxicity. The aim of this study was to assess how widely this technique is being applied in current practices as well as physicians' perceived barriers toward its implementation.

Methods: An online survey assessing the use of intraprostatic focal boost was conducted on RedCAP in December 2022. The survey link was distributed to radiation oncologists worldwide via email list, group text platform, and social media.
Results: The survey collected 205 responses from various countries over a two-week period. The majority of respondents worked at an academic medical center (59%) and considered their practice to be at least partially genitourinary (GU)-subspecialized (81%). 51% of participants reported not routinely using intraprostatic focal boost. Even among complete subspecialists, a substantial proportion (38%) do not routinely use focal boost. Less than half of participants in both high-income and low-to-middle-income countries were shown to routinely use focal boost. The most commonly cited barriers overall were challenges to accessing high-quality MRI, concerns about registration accuracy between MRI and CT, and concerns about risk of additional toxicity.
Conclusion: Despite the promising level 1 results of the FLAME trial, there is substantial evidence that most radiation oncologists are not routinely offering focal RT boost. Adoption of this technique might be accelerated by increased access to high-quality MRI, better registration algorithms of MRI to CT simulation images, physician education on benefit-to-harm ratio, and physician training on contouring prostate lesions on MRI.

Introduction:

A phase III randomized controlled trial (FLAME) demonstrated that a focal radiotherapy (RT) boost to tumors visible on MRI improves outcomes for patients with prostate cancer[1]. Participants were randomly assigned to receive either uniform RT dose to the entire prostate (control arm) or RT to the entire prostate with a focal RT dose boost to gross disease (focal boost arm). Compared to the control arm, participants in the focal boost arm had improved disease-free survival, improved local control, and improved regional/distant metastasis-free survival[1,2]. No difference in toxicity was observed between the two groups[1]. Thus, there is level 1 evidence that a meaningful oncologic benefit can be offered patients with prostate cancer without increased side effects, and this can be achieved on widely available RT equipment. Two years after first publication of the FLAME, we sought to learn whether patients are currently able to access this benefit.

Radiation dose and heterogeneity (*i.e.*, focal boost) are not, to our knowledge, routinely captured in most centers. Patients may not be aware of whether they are receiving focal boost or whether this approach was even considered for them. We decided to directly survey radiation oncologists to ask if they have adopted the focal boost approach. If some oncologists are offering focal boost and others are not, this clearly implies a new healthcare disparity created by differential adoption. We also asked survey respondents about perceived barriers to implementation of focal boost in their own practice.

Methods:

In December 2022, we conducted an international survey of radiation

oncologists. In designing the survey, we recognized two challenges. First, we are not aware of a global list of all radiation oncologists, which would be required for a survey of the complete population or to identify a random sample of that population. Second, even if all radiation oncologists could be contacted, it is likely only a small percentage would choose to participate, making accurate generalization of results impossible. Thus, robust generalizability may not be feasible. Still, a survey with a large number of responses from a diverse group of participants can be informative about practice patterns. We opted for a pragmatic approach: a group of authors from varied practice settings (country of practice; academic or private; urban, suburban, or rural) agreed to advertise the survey through electronic media. While this approach would not allow formal generalization of results, we would be able to cast a wide net and obtain enough responses to meet the primary study goals: (1) determine whether a substantial group of radiation oncologists exists that has not already adopted focal boost for prostate cancer, and (2) gain some insight into perceived barriers to adoption.

The study was approved by the Institutional Review Board at UC San Diego. Participants gave consent electronically. The survey was designed to be very brief to encourage participation (no more than 10 minutes, with initial feedback suggesting typical completion in less than 3 minutes).

We advertised the survey to our respective contacts via email and social media. We also used a previously curated email list of 850 members of the American Society for Radiation Oncology (ASTRO) practicing in the New England region of the United States and a group text platform for members of Sociedad Mexicana de Radioterapeutas (SOMERA) with 291 users. Participants were asked to consent

electronically; they self-reported as practicing radiation oncologists who treat patients with prostate cancer.

The survey included 12 questions (Supplementary Material). We asked participants whether they use focal boost and for how many cases they typically use it per month. We also asked how often they incorporate MRI into treatment planning for prostate cancer, how many prostate cancer cases they treat in a typical month, and the degree to which their practice was genitourinary (GU)-subspecialized. We asked about fractionation schemes employed when using focal boost, how often radiologists help identify prostate tumors on imaging for treatment planning, main barriers to implementing focal boost more often in their practice, and demographic information, including practice setting and years of radiation oncology experience. Finally, we conducted subgroup analyses for respondents from high-income or low-to-middle-income countries, as defined by the World Bank[3].

Results:

A total of 205 responses were collected over a two-week period in December 2022 (12/6/2022-12/20/2022). The highest-represented countries were the United States (37%), Mexico (16%), and the United Kingdom (10%). The majority of respondents (81%) considered their practice to be at least partially GU-focused: 33% completely or nearly completely GU-focused (“subspecialists”), 48% partially GU-focused (“partial subspecialists”), and 19% not GU-focused (“generalists”). Additional participant characteristics are shown in **Table 1**.

Table 1. Participant characteristics.

Practice setting	**n (%)**
Academic medical center	121 (59%)
Non-academic hospital	16 (8%)
Academic-affiliated community hospital	23 (11%)
Non-academic community hospital	11 (5%)
Independent/private practice	32 (16%)
Practice community	**n (%)**
Urban	152 (74%)
Suburban	48 (24%)
Rural	4 (2%)
Years in practice since completing training	**n (%)**
Still in training	8 (4%)
<5 years	43 (21%)
5-10 years	56 (27%)
>10 years	98 (48%)

Overall, 51% of participants do not routinely use focal boost (**Table 2**). Even among complete subspecialists, a substantial proportion (38%) do not routinely use focal boost (**Figure 1**). Less than half of generalists and partial subspecialists, respectively, report routinely using focal boost. Likewise, less than half of participants in both high-income and low-to-middle-income countries routinely use focal boost (**Figure 2**) (11 respondents did not disclose country of practice and are not included in this analysis). Additional results are shown in **Table 2**.

Table 2. Reported use of intraprostatic focal boost, by category.

Degree of GU-subspecialization	**Routinely use focal boost**	**Do not use focal boost**
Generalist (n=39)	38%	62%
Partly subspecialized (n=98)	45%	55%
Completely subspecialized (n=68)	62%	38%
Country's income*	**Routinely use focal boost**	**Do not use focal boost**
Low- to middle-income (n=67)	43%	57%
High-income (n=127)	49%	51%
Practice setting	**Routinely use focal boost**	**Do not use focal boost**
Academic medical center (n=121)	50%	50%
Non-academic hospital (n=16)	50%	50%
Academic-affiliated community hospital (n=23)	43%	57%
Non-academic community hospital (n=11)	55%	45%
Independent/private practice (n=32)	44%	56%
# of PCa cases treated per month	**Routinely use focal boost**	**Do not use focal boost**
1-4 cases (n=55)	49%	51%
5-10 cases (n=74)	41%	59%
>10 cases (n=70)	56%	44%

GU: genitourinary; PCa: prostate cancer
**As defined by the World Bank*[3]

Figure 1. Percentages of participants who routinely use intraprostatic focal boost ("Yes"), by degree of genitourinary (GU)-subspecialization.



Figure 2. Percentages of participants who routinely use intraprostatic focal boost ("Yes"), by country's income.



Perceived barriers to implementation are shown in Table 3. Write-in answers for other barriers included: not yet part of department protocol; awaiting confirmation of safety and benefit in clinical trials; too large of a tumor or absence of a clear dominant nodule on MRI; lack of standards for lesion delineation; need to justify additional workload of boost planning to physics team; and lack of access to intensity-modulated radiation therapy (IMRT) or intrafraction motion management. The most commonly cited barriers among subspecialists and partial subspecialists were concerns about registration accuracy between MRI and CT (34%), concerns about risk of additional toxicity (33%), and challenges to accessing high-quality MRI (31%). Generalists most commonly cited poor access to high-quality MRI (41%); concerns about registration between MRI and CT (31%); and lack of training on how to identify prostate tumors on MRI (28%).

Table 3. Perceived barriers to implementing intraprostatic focal boost in participants' respective practices.

	All Participants (n=205)	Generalists (n=39)	Partial Subspecialists (n=98)	Complete Subspecialists (n=68)
Not aware or convinced of benefit	22%	23%	22%	21%
Concerns about risk of additional toxicity	31%	21%	38%	26%
Challenges to accessing high-quality MRI	33%	41%	39%	19%
Concerns about registration accuracy between MRI and CT	33%	31%	35%	32%
Have not been trained to identify prostate tumors on MRI	16%	28%	16%	9%
Dosimetrists need additional training to make high-quality plans	16%	21%	14%	16%
Concerns about planning	9%	13%	8%	9%

efficiency				
Prefer brachytherapy boost	13%	8%	11%	19%
Other	16%	15%	11%	22%

Among those offering focal RT boost, participants reported using a range of dose and fractionation schemes for the prostate dose (Table 4). The most common fractionation scheme was moderate hypofractionation (2.1-3 Gy/fraction to the whole prostate) (68%), followed by ultrahypofractionation (≥6 Gy/fraction to the whole prostate) (40%). 2% of respondents selected "Other" and elaborated that they used brachytherapy boost.

Table 4. Reported fractionation schemes among participants who routinely use intraprostatic focal boost.

	All Participants (n=100)	Generalists (n=15)	Partial Subspecialists (n=44)	Complete Subspecialists (n=42)
Standard fractionation (1.8-2 Gy/fraction to the whole prostate)	26%	47%	27%	17%
Moderate hypofractionation (2.1-3 Gy/fraction to the whole prostate)	68%	53%	66%	74%
Ultrahypofractionation (≥6 Gy/fraction to the whole prostate)	40%	7%	30%	62%
Other	2%	0%	0%	5%

Discussion:

Two years after publication of level 1 evidence supporting focal RT boost, less than half of radiation oncologists responding to our survey have adopted this approach for their patients with prostate cancer. Subspecialists whose clinical practice focuses completely or nearly completely on genitourinary cancers were more likely to report use

of focal boost, but a large proportion (51%) of these experts is not routinely using focal boost. Our results show a healthcare disparity exists where only patients seeing certain physicians will even be considered for focal boost.

Participants also provided critical insight into barriers to their increased use of focal boost. Efforts to improve patient outcomes might address the most frequently cited barriers to adoption, including lack of access to high-quality MRI and concerns about accuracy of registration between MRI and CT images. Lack of access to high-quality MRI was even more common in low-to-middle-income countries but remained a commonly cited barrier in high-income countries, too. Another commonly perceived barrier among generalists is the lack of training to identify prostate tumors on MRI. Each of these three major barriers could be addressed with improved technology. For example, we have developed a novel prostate cancer MRI biomarker (called the Restriction Spectrum Imaging restriction score, or RSI_{rs}) that makes it easier to see clinically significant cancer[4–7]. RSI_{rs} can be obtained on clinical scanners with a 2-4 minute diffusion-weighted acquisition, in addition to anatomic T_2-weighted MRI. In a prospective study, use of RSI_{rs} markedly improved radiation oncologists' accuracy in identifying prostate tumors[8].

Some participants expressed doubt about the benefit of focal boost and/or concerns about additional toxicity. The former might be mitigated by inclusion of focal RT boost in continuing education materials and clinical guidelines (it was added to NCCN Guidelines in the past year, specifically for the 35-fraction regimen studied in FLAME[9]). Additional ongoing trials may also corroborate the FLAME results, encouraging adoption. Toxicity concerns are valid. While there was, on average, no

increase in toxicity in the focal boost arm in the FLAME trial, focal boost dose on that trial was only escalated to the extent feasible while meeting dose constraints to normal tissues. Additionally, some respondents had concerns about focal boost in the setting of larger doses per fraction than used in FLAME. Data on this topic are emerging. Hypo-FLAME was a phase II, single-arm study of ultra-hypofractionation (5 fractions) with focal boost and found acceptable toxicity[10]. PIVOTALboost is an ongoing phase III randomized trial in the UK evaluating focal RT boost in a 20-fraction hypofractionated regimen[11]. Ideal constraints are still under investigation, and some patients may not be good candidates for boosting[12].

Limitations of this study include self-reported practice patterns and a sample of convenience, which led to overrepresentation of physicians at academic medical centers and of genitourinary subspecialists. The survey was also very brief to encourage participation but does not provide a comprehensive picture of all aspects of practice patterns, including how physicians who do offer focal boost select candidates for this approach or how they identify the target volumes.

In conclusion, from an international survey of over 200 radiation oncologists, we found substantial evidence that most are not routinely offering focal RT boost. This is despite overrepresentation of subspecialists in genitourinary cancers, who might be earlier adopters. Based on commonly cited barriers, adoption of focal RT boost might be accelerated by increased access to high-quality MRI, better registration algorithms of MRI to CT simulation images, physician education on benefit-to-harm ratio, and physician training for how to contour prostate lesions on MRI. Addressing these barriers

would likely increase widespread adoption and the efficacy of RT for more patients with prostate cancer.

References:

1. Kerkmeijer LGW, Groen VH, Pos FJ, et al. Focal Boost to the Intraprostatic Tumor in External Beam Radiotherapy for Patients With Localized Prostate Cancer: Results From the FLAME Randomized Phase III Trial. *JCO*. 2021;39(7):787-796. doi:10.1200/JCO.20.02873

2. Groen VH, Haustermans K, Pos FJ, et al. Patterns of Failure Following External Beam Radiotherapy With or Without an Additional Focal Boost in the Randomized Controlled FLAME Trial for Localized Prostate Cancer. *European Urology*. 2022;82(3):252-257. doi:10.1016/j.eururo.2021.12.012

3. World Bank Open Data | Data. Accessed January 30, 2023. https://data.worldbank.org/

4. Conlin CC, Feng CH, Rodriguez-Soto AE, et al. Improved Characterization of Diffusion in Normal and Cancerous Prostate Tissue Through Optimization of Multicompartmental Signal Models. *J Magn Reson Imaging*. 2021;53(2):628-639. doi:10.1002/jmri.27393

5. Feng CH, Conlin CC, Batra K, et al. *Voxel-Level Classification of Prostate Cancer Using a Four-Compartment Restriction Spectrum Imaging Model*. Oncology; 2020. doi:10.1101/2020.07.25.20162172

6. Zhong AY, Digma LA, Hussain T, et al. Automated Patient-level Prostate Cancer Detection with Quantitative Diffusion Magnetic Resonance Imaging. *European Urology Open Science*. 2023;47:20-28. doi:10.1016/j.euros.2022.11.009

7. Brunsing RL, Schenker-Ahmed NM, White NS, et al. Restriction spectrum imaging: An evolving imaging biomarker in prostate MRI. *J Magn Reson Imaging*. 2017;45(2):323-336. doi:10.1002/jmri.25419

8. Lui AJ, Kallis K, Zhong AY, et al. *ReIGNITE RT Boost: An International Study Testing the Accuracy and Feasibility of Using Restriction Spectrum Imaging (RSI) MRI to Guide Intraprostatic Tumor Target Volume for Radiotherapy Boost*. Oncology; 2022. doi:10.1101/2022.12.13.22283420

9. National Comprehensive Cancer Network. Prostate Cancer (Version 1.2023). Accessed January 31, 2023. https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf

10. Draulans C, van der Heide UA, Haustermans K, et al. Primary endpoint analysis of the multicentre phase II hypo-FLAME trial for intermediate and high risk prostate cancer. *Radiotherapy and Oncology*. 2020;147:92-98. doi:10.1016/j.radonc.2020.03.015

11. Syndikus I, Cruickshank C, Staffurth J, et al. PIVOTALboost: A phase III randomised controlled trial of prostate and pelvis versus prostate alone radiotherapy with or without prostate boost (CRUK/16/018). *Clinical and Translational Radiation Oncology*. 2020;25:22-28. doi:10.1016/j.ctro.2020.08.003

12. Groen VH, van Schie M, Zuithoff NPA, et al. Urethral and bladder dose–effect relations for late genitourinary toxicity following external beam radiotherapy for prostate cancer in the FLAME trial. *Radiotherapy and Oncology*. 2022;167:127-132. doi:10.1016/j.radonc.2021.12.027